Drug Trial Radar · NCT03901469
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
115
Actual
Start
Jun 26, 2019
Primary completion
Mar 7, 2024
Study completion Mar 7, 2024
Sponsor
- Lead sponsor
- Zenith EpigeneticsIndustry
- Sponsor type
- Industry
- Collaborators
- Pfizer; Newsoara Biopharma Co., Ltd.
- First posted
- Apr 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is a dose escalation and Part 2 is a Simon 2-Stage design. There are 3 expansion cohorts: Expansion Cohort A (combination treatment in post-TROP2-ADC patients), Expansion Cohort B (ZEN003694 monotherapy), and Expansion Cohort C (combination treatment in TROP2-ADC-naive patients).
Conditions
- Triple Negative Breast Cancer
Interventions
ZEN003694Drug
PO QD
TalazoparibDrug
PO QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 and Part 2: Number of Participants With Treatment-related Adverse Events (AE) and Treatment-related Serious Adverse Events (SAE)Time frame: Cycle 1 Day 1 to 30 days post last dose (each cycle is 28 days) up to 22 months
- Part 1: Number of Participants With Dose-limiting Toxicities (DLT)Time frame: Cycle 1, Up to 1 month
- Part 2: Clinical Benefit Rate (CBR)Time frame: From screening up to 18 months
- Expansion Cohort A: Objective Response Rate (ORR) by RECIST v1.1 (CR or PR)Time frame: From screening up to 18 months
Locations
19 sites in 4 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
Emory University Winship Cancer Institute
Atlanta, Georgia
University of Kansas Cancer Center
Westwood, Kansas
Dana Farber Cancer Institute
Boston, Massachusetts
Memorial Sloan Kettering Cancer Center
New York, New York
University of Pennsylvania
Philadelphia, Pennsylvania
Tennessee Oncology (Sarah Cannon)
Nashville, Tennessee
MD Anderson
Houston, Texas
Institut Jules Bordet
Anderlecht, Belgium
UZ Leuven
Leuven, Belgium
The First Affiliated Hosptial of Bengbu Medical College
Bengbu, Anhui, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Hunan Cancer Hospital
Changsha, Hunan, China
Affliated Hospital of Jining Medical University
Jining, Shandong, China
The Second People's Hospital of Neijiang
Neijiang, Sichuan, China
Tianjing Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain
START Madrid
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.